Abraxane and Trastuzumab Followed by Dose Dense Doxorubicin and Cyclophosphamide as Neoadjuvant Therapy in Invasive Breast Cancer With Low HER2 Expression (1+ or 2+ by IHC)
Neoadjuvant (primary) chemotherapy refers to chemotherapy given before surgery. Neoadjuvant
chemotherapy has a number of potential advantages including increasing the chances for
breast preservation at the time of surgery as well as it may improve the local control of
the cancer. Several national breast cancer studies have shown that neoadjuvant chemotherapy
was equal to chemotherapy given following surgery.
A standard treatment for stage II or Stage III invasive breast cancer with low HER2
expression is combination chemotherapyAdriamycin, Cytoxan,followed by a Taxane: given either
before or after surgery), followed by surgery +/- radiation therapy.
The main purpose of chemotherapy however is to reduce the risk of recurrence of cancer and
also make surgery more successful. HER2 is a receptor located on the surface of some cells.
This receptor plays a role in regulating the growth of the cell, in addition to the growth
of tumors. High levels of the HER2 receptor may predict those women who benefit from
treatment with agents such as Herceptin that target HER2. Herceptin (Trastuzumab) is a drug
that is effective both alone and in combination with standard chemotherapy. There is some
data to suggest that patients whose tumors have low expression of the HER2 protein and are
normal by FISH may also receive benefit from Herceptin.
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Pathologic Complete Response
Qamar Khan, MD
University of Kansas Medical Center Cancer Center
United States: Institutional Review Board
|Hays Medical Center||Hays, Kansas 67601|
|University of Kansas Medical Center Cancer Center||Kansas City, Kansas 66205|